Results
Solara Active Pharma Reports FY26 ₹7.41 Crore Loss
Solara Active Pharma Sciences reported a consolidated net loss of ₹7.41 crore for FY2025-26 despite revenue growth to ₹1,368.98 crore, with significant tax litigation involving ₹607.24 crore in unreco
